1
|
Pons-Tostivint E, Daubisse-Marliac L, Grosclaude P, Oum Sack E, Goddard J, Morel C, Dunet C, Sibrac L, Lagadic C, Bauvin E, Bergé Y, Bernard-Marty C, Vaysse C, Lacaze JLL. Multidisciplinary team meeting and EUSOMA quality indicators in breast cancer care: A French regional multicenter study. Breast 2019; 46:170-177. [PMID: 31226572 DOI: 10.1016/j.breast.2019.06.001] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2019] [Revised: 04/29/2019] [Accepted: 06/03/2019] [Indexed: 12/24/2022] Open
Abstract
INTRODUCTION We evaluate breast cancer (BC) pathway at a regional level including public, private and university institutions. We assessed the quality of multidisciplinary team meetings (MTM) and compliance with a panel of European high-quality indicators (EUSOMA QIs). METHODS We conducted a retrospective multicenter (n = 20) study in the largest health care region in France. Between January and April 2015, we included all patients discussed at an MTM after a diagnosis of BC (n = 619). We analyzed quality of MTM by assessing the quorum, the reliability of data transcription and the exhaustivity of pre-therapeutic MTM. We then analyzed the compliance with a selected panel of 16 EUSOMA QIs. RESULTS During MTM discussion, data were more than 95% consistent with medical records for 9/11 items. Pre-operative tumor histology (90.6%) and post-operative resection margins (84.3%) were the least concordant between medical records and MTM. Minimum standards as defined by EUSOMA were reached for 11/16 QIs, but not reached for pathology reports in non-invasive BC (78.2%), proportion of exclusive sentinel lymph node biopsies in patients with clinically negative axilla (85.2%), performing adjuvant chemotherapy (76.6%), and proportion of patients discussed in pre-therapeutic and post-operative MTM (63.5%). CONCLUSIONS In this multicentric study evaluating the quality of BC care with a representative sample of institutions, compliance with EUSOMA indicators was satisfactory for all type of institutions. However, too few patients were discussed in pre-therapeutic MTM (especially in non-university hospitals 43.7% [39.4-48.1]) versus 88.7% for others [82.2-95.1]) and data transcription was likely responsible for up to 15% of discordance.
Collapse
Affiliation(s)
- E Pons-Tostivint
- Department of Medical Oncology, Claudius Regaud Institute, IUCT-Oncopole, Toulouse, France; Occitanie Regional Cancer Network (Onco-Occitanie), 31100, Toulouse, France.
| | - L Daubisse-Marliac
- Claudius Regaud Institute, IUCT-Oncopole, Tarn Cancer Registry, Toulouse, F-31059, France; LEASP, UMR 1027 Inserm, Université de Toulouse III, F-31000, France
| | - P Grosclaude
- Claudius Regaud Institute, IUCT-Oncopole, Tarn Cancer Registry, Toulouse, F-31059, France
| | - E Oum Sack
- Occitanie Regional Cancer Network (Onco-Occitanie), 31100, Toulouse, France
| | - J Goddard
- Occitanie Regional Cancer Network (Onco-Occitanie), 31100, Toulouse, France
| | - C Morel
- Occitanie Regional Cancer Network (Onco-Occitanie), 31100, Toulouse, France
| | - C Dunet
- Occitanie Regional Cancer Network (Onco-Occitanie), 31100, Toulouse, France
| | - L Sibrac
- Department of Medical Oncology, Claudius Regaud Institute, IUCT-Oncopole, Toulouse, France
| | - C Lagadic
- Claudius Regaud Institute, IUCT-Oncopole, Tarn Cancer Registry, Toulouse, F-31059, France
| | - E Bauvin
- Occitanie Regional Cancer Network (Onco-Occitanie), 31100, Toulouse, France
| | - Y Bergé
- Department of Medical Oncology, Clinique Claude-Bernard, Albi, France
| | - C Bernard-Marty
- Department of Medical Oncology, ONCORAD, Clinique Pasteur, Toulouse, France
| | - C Vaysse
- Toulouse University Hospital Center (CHU Toulouse), IUCT-Oncopole, 31000, Toulouse, France
| | - J L L Lacaze
- Department of Medical Oncology, Claudius Regaud Institute, IUCT-Oncopole, Toulouse, France
| | | |
Collapse
|
2
|
Dalenc F, Ribet V, Rossi A, Guyonnaud J, Bernard-Marty C, de Lafontan B, Salas S, Ranc Royo AL, Sarda C, Levasseur N, Massabeau C, Levecq JM, Dulguerova P, Guerrero D, Sibaud V. Efficacy of a global supportive skin care programme with hydrotherapy after non-metastatic breast cancer treatment: A randomised, controlled study. Eur J Cancer Care (Engl) 2017; 27. [DOI: 10.1111/ecc.12735] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/01/2017] [Indexed: 12/24/2022]
Affiliation(s)
- F. Dalenc
- Institut Claudius Regaud; Cancer University Institute-Oncopole; Toulouse Cedex 9 Toulouse France
| | - V. Ribet
- Clinical Research Centre; Pierre Fabre Dermo-Cosmetique; Toulouse Cedex 3 France
| | - A.B. Rossi
- Global Head Clinical Division & Cosmetovigilance; Research & Development Pierre Fabre Dermo-Cosmetique; Toulouse Cedex 3 France
- Larrey Hospital; Toulouse France
| | - J. Guyonnaud
- Clinical Development Department; Clinical Research Centre; Pierre Fabre Dermo-Cosmetique; Toulouse Cedex 3 France
| | | | - B. de Lafontan
- Institut Claudius Regaud; Cancer University Institute-Oncopole; Toulouse Cedex 9 Toulouse France
| | - S. Salas
- Centre de radiotherapie et d'oncologie medicale de Beziers; Beziers France
| | - A.-L. Ranc Royo
- Centre de radiotherapie et d'oncologie medicale de Beziers; Beziers France
| | - C. Sarda
- Centre Hospitalier Inter-Communal de Castres-Mazamet; Castres France
| | | | - C. Massabeau
- Institut Claudius Regaud; Cancer University Institute-Oncopole; Toulouse Cedex 9 Toulouse France
| | - J.-M. Levecq
- Centre de radiotherapie et d'oncologie medicale de Beziers; Beziers France
| | | | | | - V. Sibaud
- Oncology and Clinical Research Units; Institut Claudius Regaud; Cancer University Institute-Oncopole; Toulouse Cedex 9 Toulouse France
| |
Collapse
|
3
|
Gérard S, Bréchemier D, Lefort A, Lozano S, Abellan Van Kan G, Filleron T, Mourey L, Bernard-Marty C, Rougé-Bugat ME, Soler V, Vellas B, Cesari M, Rolland Y, Balardy L. Body Composition and Anti-Neoplastic Treatment in Adult and Older Subjects - A Systematic Review. J Nutr Health Aging 2016; 20:878-888. [PMID: 27709238 DOI: 10.1007/s12603-015-0653-2] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
BACKGROUND The estimation of the risk of poor tolerance and overdose of antineoplastic agents protocols represents a major challenge in oncology, particularly in older patients. We hypothesize that age-related modifications of body composition (i.e. increased fat mass and decreased lean mass) may significantly affect tolerance to chemotherapy. METHOD We conducted a systematic review for the last 25 years (between 1990 and 2015), using US National library of Medicine Medline electronic bibliographic database and Embase database of cohorts or clinical trials exploring (i) the interactions of body composition (assessed by Dual X-ray Absorptiometry, Bioelectrical Impedance Analyses, or Computerized Tomography) with pharmacokinetics parameters, (ii) the tolerance to chemotherapy, and (iii) the consequences of chemotherapies or targeted therapies on body composition. RESULTS Our search identified 1504 articles. After a selection (using pre-established criteria) on titles and abstract, 24 original articles were selected with 3 domains of interest: impact of body composition on pharmacokinetics (7 articles), relationship between body composition and chemotoxicity (14 articles), and effect of anti-cancer chemotherapy on body composition (11 articles). The selected studies suggested that pharmacokinetic was influenced by lean mass, that lower lean mass could be correlated with toxicity, and that sarcopenic patients experienced more toxicities that non-sarcopenic patients. Regarding fat mass, results were less conclusive. No studies specifically explored the topic of body composition in older cancer patients. CONCLUSIONS Plausible pathophysiological pathways linking body composition, toxicity, and pharmacokinetics are sustained by the actual review. However, despite the growing number of older cancer patients, our review highlighted the lack of specific studies in the field of anti-neoplastic agents toxicity regarding body composition conducted in elderly.
Collapse
Affiliation(s)
- S Gérard
- Stéphane Gérard, CHU Purpan, Gérontopôle, Pavillon Junod, 170 avenue de Casselardit 31059 Toulouse Cedex 09, France, Tel: +33 6 78 94 44 22, Fax: +33 5 61 77 64 14, E-mail address:
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Taillibert S, Conforti R, Bonneterre J, Bachelot T, Le Rhun E, Bernard-Marty C. Métastases cérébrales de cancer du sein : traitements systémiques. Cancer Radiother 2015; 19:36-42. [DOI: 10.1016/j.canrad.2014.12.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2014] [Accepted: 12/01/2014] [Indexed: 11/30/2022]
|
5
|
Bernard-Marty C, Laborie S, Lapreses E, François CL, Rivera P, Salignon K, Loste F, Mourey L, Balardy L. Standardization of the geriatric assessment within the Midi-Pyrenees Unite de Coordination in Oncogeriatrie. J Geriatr Oncol 2013. [DOI: 10.1016/j.jgo.2013.09.093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
6
|
Aapro M, Bernard-Marty C, Brain E, Batist G, Erdkamp F, Krzemieniecki K, Leonard R, Lluch A, Monfardini S, Ryberg M, Soubeyran P, Wedding U. Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Ann Oncol 2011; 22:257-67. [DOI: 10.1093/annonc/mdq609] [Citation(s) in RCA: 123] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
Bedard P, Bedard P, Mook S, Mook S, Knauer M, Knauer M, Durbecq V, Bernard-Marty C, Glas A, Cardoso F, Cardoso F, van 't Veer L, van 't Veer L. The 70-Gene Profile (MammaPrintTM) Is an Independent Predictor of Breast Cancer Specific Survival for Women 65 Years of Age or Older. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-4049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: One-half of all new breast cancer diagnoses occur in women age 65 years or older. In this age group, the use of adjuvant chemotherapy is largely influenced by co-morbidity and little is known about the applicability of prognostic multi-gene assays. The 70-gene profile (MammaPrint) is an independent prognostic indicator in early breast cancer, however, its performance in women with breast cancer 65 years or older has not been systematically studied.Methods: Women 65 years or older who were diagnosed at the Jules Bordet Institute and the Netherlands Cancer Institute between 1987 and 2003 with primary breast cancer with 0-3 involved lymph nodes who received either no adjuvant systemic therapy or adjuvant hormonal therapy alone were selected. MammaPrint test results were compared with clinical-pathological risk assessment using Adjuvant!Online.Results: Of 204 women aged 65 years or older (median age 70 years), 129 (63.2%) were classified as genomic low risk and 75 (36.8%) as genomic high risk. After a median follow-up of 8.6 years (range 0.3-17.9), the 5- and 10-year breast cancer specific survival (BCSS) for the genomic low risk group was 96% (SE 2%) and 86% (SE 4%) versus 82% (SE 4%) and 66% (SE 6%) for the genomic high risk group (log-rank p=0.001). In univariate analysis, MammaPrint was prognostic for 5-year BCSS (HR=5.0, 95%CI 1.8-14.1, p=0.002) and 10-year BCSS (HR=3.1, 95%CI 1.6-6.0, p=0.001). In a multivariate model adjusted for 10-year risk predicted by Adjuvant!Online, MammaPrint was independently prognostic for 5-year BCSS (HR=4.4, 95%CI 1.6-12.7, p=0.005) and 10-year BCSS (HR=2.5, 95%CI 1.3-5.0, p=0.009). As in prior validation series, the performance of MammaPrint was time dependent, with improved prognostication for early BCSS (≤5 years).Conclusion: Although a smaller proportion of breast cancers diagnosed in women 65 years or older are classified as high-risk by MammaPrint, it is an independent prognostic indicator that may be useful to select patients that can safely forego adjuvant chemotherapy. Additional data from patients over 70 years of age will be available at the time of the meeting. If these data are confirmatory, the ongoing prospective MINDACT trial will be amended to include older women.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 4049.
Collapse
Affiliation(s)
| | | | - S. Mook
- 2Netherlands Cancer Institute, The Netherlands
| | - S. Mook
- 3TRANSBIG Consortium, Belgium
| | - M. Knauer
- 2Netherlands Cancer Institute, The Netherlands
| | | | | | | | - A. Glas
- 4Agendia BV, The Netherlands
| | | | | | | | | |
Collapse
|
8
|
Durbecq V, Ameye L, Veys I, Paesmans M, Desmedt C, Sirtaine N, Sotiriou C, Bernard-Marty C, Nogaret J, Piccart M, Larsimont D. A significant proportion of elderly patients develop hormone-dependant “luminal-B” tumours associated with aggressive characteristics. Crit Rev Oncol Hematol 2008; 67:80-92. [DOI: 10.1016/j.critrevonc.2007.12.008] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2007] [Revised: 12/11/2007] [Accepted: 12/19/2007] [Indexed: 11/26/2022] Open
|
9
|
Bernard-Marty C, Cardoso F, Sotiriou C, Piccart MJ. [Towards an individualization of systemic treatment of breast tumors]. Bull Cancer 2006; 93:791-7. [PMID: 16935784] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
Clinical trials of adjuvant treatment of breast cancers have been limited for a long time to overall comparisons of heterogeneous populations. A new generation of clinical trials should be implemented, with especially the selection of the patients as a function of the molecular characteristics of their tumour. Unquestionable biological data must be taken into account to raise relevant questions, such as the role of topoisomerase II in the response to anthracyclines or the role of p53 in the response to taxanes. Microarrays technology, which allows the establishment of expression profiles of the whole genome, are very powerful tools which have allowed to reclassify breast tumours and to obtain "molecular signatures" characteristic for the risk of metastatic recurrence. A large randomised prospective study has been recently initiated with the aim of comparing the prognostic value of this signature to that of classical histopathologic criteria. In the next future, it will be possible to consider an individualisation of the prescription of cancer chemotherapies on molecular validated bases.
Collapse
Affiliation(s)
- C Bernard-Marty
- Département de médecine, Institut Jules-Bordet, Bruxelles, Belgique
| | | | | | | |
Collapse
|
10
|
Azambuja E, Paesmans M, Bernard-Marty C, Beauduin M, Vindevoghel A, Cornez N, Focan C, Tagnon A, Nogaret JM, Piccart-Gebhart M. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide (EC or HEC) with cyclophosphamide, methotrexate, and fluorouracil (CMF) in 777 women with node-positive (N+) breast cancer (BC): 10-year follow-up results. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.568] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
568 Background: The purpose of this presentation is to provide an update, with longer follow up data, of the results of this Belgian multicentric trial, which had shown a dose response curve for epirubicin at a median follow up of 4 years (Piccart et al, J Clin Oncol 2001; 19:3103–3110) Methods: In this prospective, open label, randomized trial of the 1990’s, patients aged from 18 to 70 years were stratified by center, 1–3 vs 4 or more nodes, and menopausal status (pre- vs postmenopausal). The primary hypothesis was that HEC could be associated with an increase in event-free survival (EFS) compared with CMF. Patients received CMF (oral cyclophosphamide days 1–14) for six cycles, EC (epirubicin 60 mg/m2, cyclophosphamide 500 mg/m2 day 1 every 3 weeks) for eight cycles or HEC (epirubicin 100 mg/m2, cyclophosphamide 830 mg/m2 day 1 every 3 weeks) for eight cycles. Tamoxifen followed chemotherapy in postmenopausal women with positive or unknown hormone receptor (HR). Two hundred fifty-five, 267, and 255 eligible patients were treated with CMF, EC, and HEC, respectively. Results: The trial results are now updated, with an actuarial median follow-up of 12.2 years. Using Kaplan-Meier estimation, the 10-year EFS is 55% for patients who received CMF, 48% for EC patients, and 58% for HEC patients. The hazard ratios obtained from Cox regression models (HR) are, for EC vs HEC, 1.30 (95% confidence interval [CI], 1.02 to 1.67, P = .03); for CMF vs HEC, 1.12 (95% CI, 0.87 to 1.44, P = .39); and for CMF vs EC, 1.17 (95% CI, 0.92 to 1.48, P = .21). Kaplan-Meier estimates of the 10-year overall survival rates are 65% for patients who received CMF, 65% for EC patients, and 70% for HEC patients, with no significant differences among the three arms. Conclusions: The short term results of this trial are nicely confirmed at 10 years: in patients unselected for HR or HER-2 status, the dose intensity of epirubicin matters. Analysis in subsets of patients is ongoing, but will be only hypothesis-generating. [Table: see text]
Collapse
Affiliation(s)
- E. Azambuja
- Jules Bordet Institute, Brussels, Belgium; Hôpital de Jolimont-Lobbes, La Louvière, Belgium; Clinique St. Elisabeth, Namur, Belgium; CHU de Tivoli, La Louvière, Belgium; Clinique St. Joseph, Liège, Belgium; Réseau Hospitalier de Médecine Sociale, Tournai, Belgium
| | - M. Paesmans
- Jules Bordet Institute, Brussels, Belgium; Hôpital de Jolimont-Lobbes, La Louvière, Belgium; Clinique St. Elisabeth, Namur, Belgium; CHU de Tivoli, La Louvière, Belgium; Clinique St. Joseph, Liège, Belgium; Réseau Hospitalier de Médecine Sociale, Tournai, Belgium
| | - C. Bernard-Marty
- Jules Bordet Institute, Brussels, Belgium; Hôpital de Jolimont-Lobbes, La Louvière, Belgium; Clinique St. Elisabeth, Namur, Belgium; CHU de Tivoli, La Louvière, Belgium; Clinique St. Joseph, Liège, Belgium; Réseau Hospitalier de Médecine Sociale, Tournai, Belgium
| | - M. Beauduin
- Jules Bordet Institute, Brussels, Belgium; Hôpital de Jolimont-Lobbes, La Louvière, Belgium; Clinique St. Elisabeth, Namur, Belgium; CHU de Tivoli, La Louvière, Belgium; Clinique St. Joseph, Liège, Belgium; Réseau Hospitalier de Médecine Sociale, Tournai, Belgium
| | - A. Vindevoghel
- Jules Bordet Institute, Brussels, Belgium; Hôpital de Jolimont-Lobbes, La Louvière, Belgium; Clinique St. Elisabeth, Namur, Belgium; CHU de Tivoli, La Louvière, Belgium; Clinique St. Joseph, Liège, Belgium; Réseau Hospitalier de Médecine Sociale, Tournai, Belgium
| | - N. Cornez
- Jules Bordet Institute, Brussels, Belgium; Hôpital de Jolimont-Lobbes, La Louvière, Belgium; Clinique St. Elisabeth, Namur, Belgium; CHU de Tivoli, La Louvière, Belgium; Clinique St. Joseph, Liège, Belgium; Réseau Hospitalier de Médecine Sociale, Tournai, Belgium
| | - C. Focan
- Jules Bordet Institute, Brussels, Belgium; Hôpital de Jolimont-Lobbes, La Louvière, Belgium; Clinique St. Elisabeth, Namur, Belgium; CHU de Tivoli, La Louvière, Belgium; Clinique St. Joseph, Liège, Belgium; Réseau Hospitalier de Médecine Sociale, Tournai, Belgium
| | - A. Tagnon
- Jules Bordet Institute, Brussels, Belgium; Hôpital de Jolimont-Lobbes, La Louvière, Belgium; Clinique St. Elisabeth, Namur, Belgium; CHU de Tivoli, La Louvière, Belgium; Clinique St. Joseph, Liège, Belgium; Réseau Hospitalier de Médecine Sociale, Tournai, Belgium
| | - J. M. Nogaret
- Jules Bordet Institute, Brussels, Belgium; Hôpital de Jolimont-Lobbes, La Louvière, Belgium; Clinique St. Elisabeth, Namur, Belgium; CHU de Tivoli, La Louvière, Belgium; Clinique St. Joseph, Liège, Belgium; Réseau Hospitalier de Médecine Sociale, Tournai, Belgium
| | - M. Piccart-Gebhart
- Jules Bordet Institute, Brussels, Belgium; Hôpital de Jolimont-Lobbes, La Louvière, Belgium; Clinique St. Elisabeth, Namur, Belgium; CHU de Tivoli, La Louvière, Belgium; Clinique St. Joseph, Liège, Belgium; Réseau Hospitalier de Médecine Sociale, Tournai, Belgium
| |
Collapse
|
11
|
Bernard-Marty C, Demonty G, Personeni N, Ismael G, Cardoso F, Kabanga E, Bexon A, Nogaret J, Biganzoli L, Piccart M. Capecitabine as adjuvant therapy for elderly breast cancer (BC) patients (pts): a pilot study. EJC Suppl 2006. [DOI: 10.1016/s1359-6349(06)80384-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
12
|
Abstract
Taxanes are currently introduced early in the treatment of patients with metastatic breast cancer (MBC), both as single agents and in combination with anthracyclines. Two different patient populations exist: those with no or minimal prior anthracycline exposure and those who have failed previous anthracyclines. The data generated through phase III trials in first-line MBC therapy will be reviewed and their interpretation for routine clinical practice (use versus abuse) will be discussed. Ways of improving taxane-based treatment tailoring both in the pre- and postgenomic eras will be addressed.
Collapse
Affiliation(s)
- C Bernard-Marty
- Department of Medical Oncology, Jules Bordet Institute, Boulevard de Waterloo, 215, 1000, Brussels, Belgium
| | | | | |
Collapse
|
13
|
Bernard-Marty C, Mano M, Paesmans M, Accettura C, Munoz-Bermeo R, Richard T, Kleiber K, Cardoso F, Lobelle JP, Larsimont D, Piccart MJ, Di Leo A. Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients. Ann Oncol 2003; 14:693-8. [PMID: 12702521 DOI: 10.1093/annonc/mdg204] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Alkylating agents and topoisomerase-II inhibitors have been associated with the occurrence of secondary leukemias and myelodysplastic syndromes in breast cancer patients treated with adjuvant chemotherapy. Conversely, data on the occurrence of second solid malignancies in this setting are scarce. PATIENTS AND METHODS This study retrospectively evaluates the occurrence of second hematological and solid malignancies in the context of a prospective multicenter phase III trial comparing epirubicin-cyclophosphamide at intermediate doses (EC), or at full doses (HEC), with classical cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in 777 patients with early breast cancer. RESULTS At a median follow-up of 73 months, the following 8-year actuarial rates of second solid primaries were observed: CMF 5.5% [95% confidence interval (CI) 1.5% to 9.5%], EC 4.1% (95% CI 0.1% to 8.1%), and HEC 7.2% (95% CI 3.2% to 11.2%) (P = 0.79 by log rank test). Three secondary acute myeloid leukemias (AML) were reported, all in the HEC arm (incidence = 1.2%, 95% CI 0.0% to 2.5%), which by a three arm comparison allows us to conclude that HEC is statistically different (borderline significance) from CMF and EC (P = 0.05). CONCLUSIONS HEC, as delivered in this trial, cannot be recommended in clinical practice because of the lack of superiority over classic CMF and because of the increased risk of AML observed in this arm. Prolongation of conventional anthracycline-based treatment beyond the current standard of four to six cycles is not recommended in clinical practice.
Collapse
|
14
|
Gancberg D, Di Leo A, Cardoso F, Rouas G, Pedrocchi M, Paesmans M, Verhest A, Bernard-Marty C, Piccart MJ, Larsimont D. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002; 13:1036-43. [PMID: 12176781 DOI: 10.1093/annonc/mdf252] [Citation(s) in RCA: 256] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
BACKGROUND The humanized anti-HER-2 monoclonal antibody trastuzumab (Herceptin) is a new treatment modality for metastatic breast cancer, the efficacy of which is directly correlated with the HER-2 status of the tumour, evaluated either by immunohistochemistry (IHC) and/or by fluorescence in situ hybridisation (FISH). This analysis is generally performed on the primary tumour. There are few data regarding the HER-2 status in the corresponding distant metastases. METHODS HER-2 status in 107 patients with a primary breast tumour and at least one distant metastatic lesion was analysed by IHC and FISH. RESULTS We found similar levels of amplification (25% and 24%) and overexpression (13% and 19%) of HER-2 in primary and metastatic samples, respectively. Among paired primary/metastatic tumours, six (6%) showed discordance by HercepTest(TM) (n = 100): all six cases showed greater Her-2 overexpression in the metastatic tissue. By FISH (n = 68), five (7%) cases were discordant: two cases were amplified in the primary tumour but not in the metastasis, and three samples showed amplification in the metastasis but not in the primary. Finally, we analysed HER-2 status in different metastatic lesions from 17 patients that had at least two distant metastatic sites. Discordance between different sites from the same patient was 18% by IHC and 19% by FISH. CONCLUSIONS Between the paired primary tumour and distant metastatic lesions, 94% and 93% of samples had concordant HER-2 status when analysed by IHC or FISH, respectively. These results do not support routine determination of HER-2 on metastatic sites, particularly when FISH results from the primary tumour are available.
Collapse
Affiliation(s)
- D Gancberg
- Translational Research Unit and Data Centre, Jules Bordet Institute, Brussels, Belgium
| | | | | | | | | | | | | | | | | | | |
Collapse
|